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Abstract
Background: Addison’s disease, or primary adrenal insufficiency, is often associated with reduced well-being and fatigue
despite use of currently recommended adrenal hormone replacement. Hypoglycaemia is a known manifestation of
glucocorticoid deficiency, but is generally considered rare in adults and not relevant to troubling ongoing symptoms in
patients with Addison’s disease.
Case presentation: A 43 year old woman with a three year history of Addison’s disease complained of severe morning
fatigue and headaches, despite standard glucocorticoid replacement therapy in the form of thrice daily hydrocortisone
and mineralocorticoid replacement with fludrocortisone. Alternative glucocorticoid replacement regimens and the
addition of dehydroepiandrosterone replacement therapy had no effect. Nocturnal hypoglycaemia was suspected and a
4-day continuous glucose monitor system (CGMS) revealed hypoglycaemia (interstitial glucose < 2.2 mmol/L) between
0200–0400 h on 3 of 4 days. The patient was counselled to take an evening snack designed to ensure slow absorption of
ingested carbohydrates. Nocturnal hypoglycaemia was then absent on follow up CGMS assessment. The patient noted a
marked symptomatic improvement in morning symptoms, but with persistent fatigue during the day.
Conclusion: Currently, the best strategy for control of non-specific symptoms in treated Addison’s disease is unknown,
but it may be that investigation for hypoglycaemia and treatment, where necessary, could assist some sufferers to
achieve improved wellbeing. A systematic study of this phenomenon in Addison’s disease is required.
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Background
Addison’s disease or primary adrenal insufficiency
(PAI) is managed with adrenal hormone replacement
(glucocorticoid and mineralocorticoid). Ongoing fatigue
despite best practice hormone replacement is a clinical
problem [1, 2]. Treated patients are not regarded as being
at risk of hypoglycaemia despite loss of the glucose
elevating effects of glucocorticoids (GC) [3]. We describe
a patient with nocturnal hypoglycaemia diagnosed on
continuous glucose monitoring that had resolved with
a late evening dietary supplement with attendant
improvement in morning fatigue and headache. This
problem may be more frequent than recognised and a
systematic study is required.
Case presentation
The patient was a 43 year old Caucasian woman who
had a three year history of diagnosed Addison’s disease
(PAI). At the time of presentation with PAI, she reported
weight loss of at least 4 kg over 6 months, fatigue and
hyperpigmentation. Biochemistry revealed a serum sodium
of 132 mmol/L (R 137–145 mmol/L) and potassium of
5.4 mmol/L (R 3.5–4.9 mmol/L), plasma cortisol of
16 nmol/L and an ACTH level of 1097 pmol/L (R 10–60
pmol/L). A 250mcg ACTH stimulation test showed a non-
significant rise in serum cortisol from baseline 16 nmol/L
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to 17 nmol/L (R >500 nmol/L) at both 30 and 60 min. The
plasma renin concentration was > 500 uIU/mL (R 7–50
uIU/mL) and plasma aldosterone <30 pmol/L (110–860
pmol/L). Primary hypothyroidism was evident with a TSH
of 46 mIU/mL (R 0.5-4.0 mIU/mL) and a free T4 of
10 nmol/L (R 10–25 nmol/L). Elevated thyroid peroxidase
antibodies and a firm small goitre were consistent with
Hashimoto’s disease. Twelve months before diagnosis of
PAI, mild normocytic anaemia was detected; Hb 89 g/L
and biochemically confirmed iron deficiency (ferritin 12 μg/
L [15–250 μg/L], transferrin saturation 6 % [10-35 %],
transferrin 2.79 g/L [2.0-4.0 g/L], with normal B12 and
folate levels. Oral iron supplements led to recovery of
anaemia and normal iron studies. At the time of diagnosis
of PAI she was found to have strongly positive endomysial
and gliadin antibodies, consistent with coeliac disease,
confirmed on jejunal biopsy. Adrenal hormone replacement
included hydrocortisone (HC), initially in a thrice daily regi-
men at 0700 h, 1200 h, 1600 h in doses of 10/10/4 mg
respectively, fludrocortisone 0.1 mg daily (after initial
lower doses due to oedema), thyroxine 75mcg daily and
a gluten free diet. Follow up revealed improved well-being,
normalization of electrolytes, haemoglobin, plasma renin
and TSH, as well as resolution of coeliac antibodies and a
normal jejunal biopsy.
However, ongoing fatigue prompted trials of various GC
regimens. Prednisolone 5 mg in the morning and 1–2 mg
afternoon (0700 h, 1400 h) was not effective in relieving
fatigue and a thrice daily regimen (0600 h, 1145 h, 1700 h)
of HC 10/8/5 mg, equating to a total dose of 0.44 mg/kg
or 15 mg/m2 was employed, encompassing the period
where CGMS measures were later performed. A trial of
dehydroepiandrosterone (DHEA) was used in an attempt
to alleviate the patient’s fatigue in doses up to 25 mg daily
with normalization of DHEA levels that were initially
undetectable. Unfortunately, this resulted in subtle hir-
sutism with hair growth around the chin and sideburn
area, and the dose was reduced by the patient down to
5 mg daily; overall there was no consistent effect of
DHEA on wellbeing.
No definite cause for the patient’s ongoing fatigue could
be determined on clinical grounds. A particular character-
istic of the fatigue was its severity and timing, occurring
each morning and described by the patient as “extreme”
“very hard to get up” “like being hit by a train” subse-
quently taking approximately 20 min to significantly
resolve, after the usual morning HC and breakfast. There
were also frequent non-migrainous morning headaches.
There was no consistent excessive nocturnal wakening
but poor or broken sleep was encountered on occasion.
There were no episodes of nocturnal diaphoresis.
Hypoglycaemia was suspected and a continuous glu-
cose monitor system (CGMS) was used to collect inter-
stitial glucose levels over four days (Fig 1a). The CGMS
revealed hypoglycaemia on three of four days tested,
which was lasted up to six hours throughout one night.
Calibration was performed against finger prick blood
glucose levels (BGL), which were performed four times
daily (i.e. before each meal and before bed). Dietary ma-
nipulation to address the hypoglycaemia was attempted
and the patient was advised to have an evening low
glycaemic index (GI) snack incorporating a fat load;
specifically a whole-grain rice cake or multi-grain
gluten free bread topped with cheese, cream cheese or
peanut butter. The patient consumed this snack be-
tween 2030–2100 h during a repeat period of CGMS
assessment, which was performed over seven days. The
repeat CGMS measurements (Fig. 1b) showed reso-
lution of the hypoglycaemia. The CGMS values were
validated as per usual practice against finger prick
capillary blood glucose values. The dietary changes
resulted in resolution of headaches and improved
energy after waking, although there was persistent day-
time fatigue.
Discussion
This patient had a background of PAI, concomitant pri-
mary hypothyroidism due to Hashimoto’s disease, and
coeliac disease, consistent with autoimmune polyglandu-
lar syndrome type 2 (APS-2). Treatment included GC
and mineralocorticoid replacement, thyroxine and a
gluten free diet. Severe morning fatigue and headaches
were noted and CGMS revealed recurrent prolonged
nocturnal hypoglycaemia. The use of an evening dietary
intervention alleviated symptoms and CGMS evidence
of hypoglycaemia. We suggest that PAI patients with
symptoms such as marked fatigue, headaches or unex-
plained diaphoresis, particularly if nocturnal or on wak-
ing, be screened for hypoglycaemia and, if present,
dietary measures may provide a simple strategy for
improved well-being.
Physical and mental fatigue, stress, anxiety and impaired
concentration (“L’encephalothie addisonne”) are well rec-
ognized symptoms of adrenal insufficiency (AI) that are
associated with many aspects of reduced quality of life in
patients and often persist despite optimal treatment [1, 2].
It has been suspected that the use of oral GCs, which ne-
cessarily lead to cortisol levels that do not precisely mimic
the normal circadian rhythm or produce brief ultradian
pulses of cortisol secretion may underlie impaired quality
of life in those with PAI.
Retrospective studies of individuals taking long acting
GCs such as prednisolone and dexamethasone have
suggested a predisposition towards reduced well-being
in AI patients [4] in addition to an increased risk of
lower bone mineral density [5], increased hip fracture
rates [6] and higher levels of abdominal adiposity with
dysplipidaemia [7]. These results have prompted a trend
Petersen et al. BMC Endocrine Disorders  (2015) 15:61 Page 2 of 5
towards the use of short-acting, low dose HC rather than
longer acting synthetic GCs [8, 9]. However, these low
dose, short-acting HC schedules invoke both variable
cortisol levels [10] and nocturnal hypocortisolism due to
the duration of action of HC, plasma disappearance
half-life 90 mins, duration of effect 3 h [11, 12]. Noc-
turnal hypocortisolism may be exacerbated by the use
of short-acting HC, which combined with the effects
of fasting, may increase the risk of hypoglycaemia.
Episodic hypocortisolism has the potential to increase
the risk of adrenal crises as there is an epidemio-
logical association in one study between increased
use of short-acting GC and increased rates of adrenal
crises, but prospective studies of this association are
not available and other factors may have contributed
to apparent rising rates of adrenal crises in recent
years [8, 9].
Late dosing of GCs is sometimes associated with sleep
difficulties, presumably due to the known effects of GCs
on arousal [13]. Hence, studies of GC regimens have
focussed on short-acting GCs given at various frequen-
cies, but avoiding administration 4–6 h before bedtime,
in an attempt to mimic circadian plasma cortisol levels
and improve short-term non-blinded measures of quality
of life. Two studies have shown that circadian cortisol
rhythms are closer to physiological if HC is given on a
thrice-daily 10/5/5 mg schedule [14, 15]. Weight related
dosing reduces inter-individual variation in cortisol levels
[16]. Cortisone acetate, which is converted to HC en-
dogenously, has been shown to produce greater ACTH
suppression and more physiological cortisol levels in
Addison’s when given as a thrice rather than twice daily
regimen [17, 18]. A four-dose regimen of HC produced
more physiological circadian cortisol levels than 2-dose,
Fig. 1 Continuous glucose monitoring before (a) and after (b) the dietary manipulation in the patient with treated Addison’s disease
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but quality of life was similar [19, 20]. A practical limita-
tion is the patients reported difficulty in adherence to fre-
quent dose schedules [21]. Overall, although these studies
have shown that more frequent GC dosing can more
closely mimic physiological cortisol levels there is limited
short term data on quality of life and the optimum GC
replacement regimen in PAI is not known.
Studies of two types of sustained release HC, once
daily dual release Plenadren and twice daily enteric
coated Chronocort, have shown more physiological cir-
cadian cortisol profiles than regular HC [22]. In the case
of Plenadren, metabolic studies have revealed lower
HbA1c, waist circumference and LDL cholesterol despite
similar cortisol peaks and integrated values and lower
ACTH levels in patients with Addison’s switching from
HC to Plenadren [23]. Blinded controlled studies, using
a visually identical rapid release HC preparation to
assess the effect on well-being, have not been performed
[24, 25]. Improved quality of life has been reported in
patients receiving HC via an unblinded subcutaneous
infusion on a circadian schedule, although quality of life
did not change in one placebo-controlled double-blind
study [26, 27].
Administration of DHEA, an adrenal steroid that is not
secreted in appreciable amounts in PAI, has been shown
to have variable effects on wellbeing and quality of life in
several studies, but the results of a meta-analysis did not
demonstrate a consistent benefit and for this reason
DHEA is not recommended routinely [28].
Hypoglycaemia is a known manifestation of adrenal
insufficiency (AI), particularly among children [29] but is
generally considered rare in adults and not relevant to
troubling ongoing symptoms such as fatigue and reduced
vitality in treated AI. Patients with concomitant type 1
diabetes and PAI are commonly reported to have reduced
insulin requirement and some guidelines have suggested
that longer acting GCs such as prednisolone be used in
this setting [30].
Acute cortisol withdrawal in PAI patients leads to
reduced hepatic glucose output and increased glucose oxi-
dation [3]. Quantitatively, the effect of hypococortisolism
on glycaemia is large; experimentally induced hypocortiso-
lism in PAI patients was met with a requirement to increase
glucose infusion rates by 70 % to maintain a predetermined
blood glucose [3]. Relatively small doses of hydrocortisone
in the evening may alleviate hypoglycaemia, since the glu-
cose elevating effect of hydrocortisone is more marked after
evening than morning dosing of hydrocortisone [31]; the
mechanism is also time related with an immediate reduc-
tion in insulin secretion followed in 4–12 h by increased
insulin resistance [32, 33].
One study has examined the question of the preva-
lence of hypoglycaemia in PAI, using CGMS technology
[34]. Of 13 patients screened one patient, a 46 year old
man with PAI and no other comorbidities, had nocturnal
hypoglycaemia of approximately one hour duration reach-
ing a trough of 2.6 mmol/L. The hypoglycaemia resolved
on repeat CGMS assessment with administration of the
last HC dose in the late evening. In this case the apparent
symptoms were frequent waking at night, which settled
with the delayed HC administration.
Conclusions
We suggest that the use of CGMS assessment in selected
cases may help detect hypoglycaemia and that simple
and safe dietary manipulations similar to that described
above, may help to resolve the hypoglycaemia. Alterna-
tive strategies may include the administration of GC
later in the day, such as the evening, however there is a
risk of disturbed sleep as discussed above. We suggest
that further studies are required, perhaps focussing on
those with early morning symptomatology, to determine
the frequency of hypoglycaemia in patients with PAI.
When detected, appropriate dietary manipulation or the
use of long-acting glucococorticoids may allow improve-
ment in symptoms, an important issue as reduced qual-
ity of life and wellbeing occur in a substantial proportion
of patients with PAI.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor of this journal.
Abbreviations
ACTH: Adrenocorticotropic hormone; AI: Adrenal insufficiency;
APS-2: Autoimmune polyglandular syndrome type 2; BGL: Blood glucose levels;
CGMS: Continuous glucose monitor system; DHEA: Dehydroepiandrosterone;
GC: Glucocorticoid; GI: Glycaemic index; HC: Hydrocortisone; PAI: Primary adrenal
insufficiency; TSH: Thyroid-stimulating hormone; QID: Four times per day.
Competing interests
The authors declare that they have no competing interests.
Author’s contributions
KSP dietary management, drafting and reviewing the manuscript. RLR reviewed
and drafted the manuscript. PMC dietary management and reviewing the
manuscript. DJT data interpretation, drafting and reviewing the manuscript.






1Dietitian, School of Pharmacy and Medical Sciences, University of South
Australia, GPO Box 2471, Adelaide SA 5000, Australia. 2School of Medicine,
Sydney, The University of Notre Dame, 60 Oxford St., Darlinghurst NSW 2010,
Australia. 3School of Pharmacy and Medical Sciences, University of South
Australia, GPO Box 2471, Adelaide SA 5000, Australia. 4Endocrine and
Metabolic Unit, Royal Adelaide Hospital, University of Adelaide, North
Terrace, Adelaide SA 5000, Australia.
Petersen et al. BMC Endocrine Disorders  (2015) 15:61 Page 4 of 5
Received: 13 May 2015 Accepted: 16 October 2015
References
1. Løvås K, Loge JH, Husebye ES. Subjective health status in Norwegian
patients with Addison’s disease. Clin Endocrinol. 2002;56(5):581–8.
2. Meyer G, Hackemann A, Penna-Martinez M, Badenhoop K. What affects the
quality of life in autoimmune Addison's disease? Horm Metab Res.
2013;45(2):92–5.
3. Christiansen JJ, Djurhuus CB, Gravholt CH, Iversen P, Christiansen JS, Schmitz
O, et al. Effects of cortisol on carbohydrate, lipid, and protein metabolism:
studies of acute cortisol withdrawal in adrenocortical failure. J Clin
Endocrinol Metab. 2007;92(9):3553–9.
4. Bleicken B, Hahner S, Loeffler M, Ventz M, Decker O, Allolio B, et al. Influence
of hydrocortisone dosage scheme on health‐related quality of life in
patients with adrenal insufficiency. Clin Endocrinol. 2010;72(3):297–304.
5. Løvås K, Gjesdal CG, Christensen M, Wolff AB, Almås B, Svartberg J, et al.
Glucocorticoid replacement therapy and pharmacogenetics in Addison's
disease: effects on bone. Eur J Endocrinol. 2009;160(6):993–1002.
6. Björnsdottir S, Sääf M, Bensing S, Kämpe O, Michaelsson K, Ludvigsson JF. Risk
of hip fracture in Addison’s disease: a population‐based cohort study. J Intern
Med. 2011;270(2):187–95.
7. Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson
G. The impact of glucocorticoid replacement regimens on metabolic
outcome and comorbidity in hypopituitary patients. J Clin Endocrinol
Metab. 2006;91(10):3954–61.
8. Rushworth RL, Torpy DJ. Modern hydrocortisone replacement regimens in
adrenal insufficiency patients and the risk of adrenal crisis. Horm Metab Res.
2015;47(9):637–42.
9. Rushworth RL, Torpy DJ. Adrenal insufficiency in Australia: is it possible that
the Use of lower dose, short-acting glucocorticoids has increased the risk of
adrenal crises? Horm Metab Res. 2015;47(6):427–32.
10. Simon N, Castinetti F, Ouliac F, Lesavre N, Brue T, Oliver C. Pharmacokinetic
evidence for suboptimal treatment of adrenal insufficiency with currently
available hydrocortisone tablets. Clin Pharmacokinet. 2010;49(7):455–63.
11. Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and
pharmacodynamics of systemically administered glucocorticoids. Clin
Pharmacokinet. 2005;44(1):61–98.
12. Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids:
effects of hydrocortisone, prednisone and dexamethasone on human
pituitary-adrenal function. Am J Med. 1977;63(2):200–7.
13. Fietta P. Glucocorticoids and brain functions. Rivista Di Biologia.
2006;100(3):403–18.
14. Peacey SR, Guo CY, Robinson AM, Price A, Giles MA, Eastell R, et al.
Glucocorticoid replacement therapy: are patients over treated and does it
matter? Clin Endocrinol. 1997;46(3):255–61.
15. Howlett TA. An assessment of optimal hydrocortisone replacement therapy.
Clin Endocrinol. 1997;46(3):263–8.
16. Mah PM, Jenkins RC, Rostami‐Hodjegan A, Newell‐Price J, Doane A, Ibbotson V,
et al. Weight‐related dosing, timing and monitoring hydrocortisone
replacement therapy in patients with adrenal insufficiency. Clin Endocrinol.
2004;61(3):367–75.
17. Laureti S, Falorni A, Santeusanio F. Improvement of treatment of primary
adrenal insufficiency by administration of cortisone acetate in three daily
doses. J Endocrinol Investig. 2003;26(11):1071–5.
18. Barbetta L, Dall’Asta C, Re T, Libe R, Costa E, Ambrosi B. Comparison of
different regimens of glucocorticoid replacement therapy in patients with
hypoadrenalism. J Endocrinol Investig. 2005;28(9):632–7.
19. Ekman B, Bachrach‐Lindström M, Lindström T, Wahlberg J, Blomgren J,
Arnqvist HJ. A randomized, double‐blind, crossover study comparing two‐and
four‐dose hydrocortisone regimen with regard to quality of life, cortisol and
ACTH profiles in patients with primary adrenal insufficiency. Clin Endocrinol.
2012;77(1):18–25.
20. Alonso N, Granada ML, Lucas A, Salinas I, Reverter J, Oriol A, et al. Evaluation
of two replacement regimens in primary adrenal insufficiency patients.
Effect on clinical symptoms, health-related quality of life and biochemical
parameters. J Endocrinol Investig. 2004;27(5):449–54.
21. Forss M, Batcheller G, Skrtic S, Johannsson G. Current practice of
glucocorticoid replacement therapy and patient-perceived health
outcomes in adrenal insufficiency-a worldwide patient survey. BMC
Endocr Disord. 2012;12(1):8.
22. Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ,
Newell-Price J, et al. Modified-release hydrocortisone to provide circadian
cortisol profiles. J Clin Endocrinol Metab. 2009;94(5):1548–54.
23. Giordano R, Guaraldi F, Marinazzo E, Fumarola F, Rampino A, Berardelli R,
et al. Improvement of anthropometric and metabolic parameters, and
quality of life following treatment with dual-release hydrocortisone in
patients with Addison’s disease. Endocrine 2015:1–9.
24. Mallappa A, Sinaii N, Kumar P, Whitaker MJ, Daley L-A, Digweed D, et al. A phase
2 study of chronocort®, a modified-release formulation of hydrocortisone, in the
treatment of adults with classic congenital adrenal hyperplasia. J Clin Endocrinol
Metab. 2014;100(3):1137–45.
25. Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T, Skrtic S.
Improving glucocorticoid replacement therapy using a novel modified-release
hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol.
2009;161(1):119–30.
26. Øksnes M, Björnsdottir S, Isaksson M, Methlie P, Carlsen S, Nilsen RM, et al.
Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone
replacement for treatment of Addison's disease: a randomized clinical trial.
J Clin Endocrinol Metab. 2014;99(5):1665–74.
27. Gagliardi L, Nenke MA, Thynne TR, von der Borch J, Rankin WA, Henley DE,
et al. Continuous subcutaneous hydrocortisone infusion therapy in Addison’s
disease: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab.
2014;99(11):4149–57.
28. Alkatib AA, Cosma M, Elamin MB, Erickson D, Swiglo BA, Erwin PJ, et al. A
systematic review and meta-analysis of randomized placebo-controlled trials of
DHEA treatment effects on quality of life in women with adrenal insufficiency.
J Clin Endocrinol Metab. 2009;94(10):3676–81.
29. Hsieh S, White PC. Presentation of primary adrenal insufficiency in childhood.
J Clin Endocrinol Metab. 2011;96(6):E925–8.
30. Elbelt U, Hahner S, Allolio B. Altered insulin requirement in patients with
type 1 diabetes and primary adrenal insufficiency receiving standard
glucocorticoid replacement therapy. Eur J Endocrinol. 2009;160(6):919–24.
31. Plat L, Leproult R, L’Hermite-Baleriaux M, Fery F, Mockel J, Polonsky KS, et al.
Metabolic effects of short-term elevations of plasma cortisol Are more
pronounced in the evening than in the morning 1. J Clin Endocrinol Metab.
1999;84(9):3082–92.
32. Van Cauter E, Leproult R, Kupfer DJ. Effects of gender and age on the levels
and circadian rhythmicity of plasma cortisol. J Clin Endocrinol Metab.
1996;81(7):2468–73.
33. Plat L, Byrne MM, Sturis J, Polonsky KS, Mockel J, Fery F, et al. Effects of
morning cortisol elevation on insulin secretion and glucose regulation in
humans. Am J Physiol. 1996;270(1):E36–42.
34. Meyer G, Hackemann A, Reusch J, Badenhoop K. Nocturnal hypoglycemia
identified by a continuous glucose monitoring system in patients with
primary adrenal insufficiency (Addison’s disease). Diabetes Technol Ther.
2012;14(5):386–8.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Petersen et al. BMC Endocrine Disorders  (2015) 15:61 Page 5 of 5
